相关实验视频
Updated: Jun 14, 2025

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
118
早期预测进展到阿尔茨海默病使用多模式神经图像的新型正则学习模型 ADPacer
Lujia Wang1, Zhiyang Zheng1, Yi Su2
1H. Hilton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology, GA USA.
IISE transactions on healthcare systems engineering
|September 6, 2024
概括
这项研究介绍了ADPacer,这是一种用于预测阿尔茨海默病 (AD) 在轻度认知障碍 (MCI) 患者中进展速度的新型机器学习模型. 通过独特地处理模两可的数据,ADPacer提高了预测准确性,超过了现有的方法.
科学领域:
- 神经科学是一个神经科学.
- 人工智能的人工智能
- 医疗成像医学成像
背景情况:
- 机器学习在整合多模式神经成像来预测轻度认知障碍 (MCI) 的阿尔茨海默病 (AD) 风险预测方面显示出前景.
- 目前的方法经常将MCI患者分类为转换者与非转换者在固定的时间范围内,在预测转换速度时缺乏细节性.
- 预测进展速度对于个性化干预,患者/护理人员准备和临床试验对象选择具有临床价值.
研究的目的:
- 开发一种新的机器学习模型,ADPacer,用于预测患有轻度认知障碍 (MCI) 的人患阿尔茨海默病 (AD) 的进展速度.
- 通过提供更细致的转换速度预测来解决现有模型的局限性.
- 利用具有标签模糊性的训练样本来增强训练集,提高模型的稳定性.
主要方法:
- 制定了节奏预测作为一个顺序学习问题.
- 开发了ADPacer,这是一种新的顺序学习算法,具有独特的能力,可以利用具有标签模糊性的训练样本.
- 将ADPacer应用于来自阿尔茨海默病神经成像计划 (ADNI) 和澳大利亚成像,生物标志物和生活方式老龄化研究 (AIBL) 的MCI患者队列.
- 综合的SHapley添加式解释 (SHAP) 来评估模式贡献.
主要成果:
- 在ADNI和AIBL数据集上,ADPacer与现有的顺序学习算法相比,表现出更好的性能.
- 该模型成功预测了MCI患者的进展速度.
- SHAP分析证实,模式贡献与已建立的阿尔茨海默病 (AD) 文献保持一致.
结论:
- 在预测MCI患者阿尔茨海默病 (AD) 进展速度方面,ADPacer提供了显著的进步.
- 该模型处理标签模糊性的能力提高了预测准确性和临床实用性.
- 这些发现支持ADPacer用于个性化医疗和优化AD研究中的临床试验设计.
更多相关视频
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
989
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
相关概念视频
Alzheimer's Disease: Overview
454
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170